Switching actions and stopping movements involve two distinct cognitive motor processes, according to a study that combined computer modeling with tasks performed by healthy people. The findings have implications for people with Parkinson’s disease, who experience longer reaction times and delays when they want to start, stop, or switch…
Physical exercise, avoiding falls, and the importance of providing support to caregivers were the focus of the 10th UAMS Parkinson’s symposium hosted last month by the University of Arkansas for Medical Sciences (UAMS), where the latest advances in diagnosing and treating people with Parkinson’s disease and atypical parkinsonism…
A $50,000 grant will allow Stockton University to provide free SPEAK OUT! voice therapy to people in New Jersey with Parkinson’s disease. Parkinson Voice Project (PVP), which is providing the grant, designed the SPEAK OUT! program to help Parkinson’s patients with motor symptoms including low speech volume, slurred…
Low-dose psilocybin, a naturally occurring psychedelic compound, may be a promising therapy for mood issues including depression and anxiety in people with Parkinson’s disease, according to data from a pilot Phase 2 clinical trial. In addition to significant reductions in depression and anxiety, results from the trial (NCT04932434)…
Blocking the inflammatory protein ASC with IC 100, ZyVersa Therapeutics’ experimental therapy to reduce inflammation, prevented the activation of the inflammasome in microglia — the brain’s resident immune cells — and the start and perpetuation of an inflammatory response. That’s according to results from a study announced by the…
Listening to rhythm-based cues while walking not only builds lasting walking habits, but also helps people with Parkinson’s disease walk more, at a greater intensity, and more steadily than walking on their own. These are the findings of a clinical study (NCT05421624) that tested MR-005, a digital tool…
The STING protein, which has been linked to cell damage and brain inflammation — two known contributing factors to Parkinson’s disease and other neurodegenerative diseases — has a dual function, a study found. The researchers said their finding could have implications for treating Parkinson’s and other neurodegenerative diseases. Lysosomes,…
The Michael J. Fox Foundation (MJFF) has awarded a $14.7 million research grant to Verily, an artificial intelligence platform for health analytics, to generate a detailed set of molecular information for Parkinson’s disease research. Verily will analyze biological samples, including blood and cerebrospinal fluid, from participants in the…
Ring-shaped small proteins called macrocyclic peptides — originally developed to target proteins linked to diabetes and Alzheimer’s disease — have now been shown in a laboratory to also prevent alpha-synuclein from forming the hallmark toxic clumps observed in Parkinson’s disease. That’s according to researchers from the Technical University of…
The Michael J. Fox Foundation (MJFF) is expanding its Parkinson’s Progression Markers Initiative (PPMI) to provide free Parkinson’s disease risk screening to people 40 years and older. The move will allow PPMI to screen more people using blood testing and tests of smell loss, a possible early…
Get regular updates to your inbox.
